TCGA-E2-A9RU-01A-11R-A41B-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.520
- CHOLESTEROL_HOMEOSTASIS+0.430
- MYC_TARGETS_V1+0.430
- OXIDATIVE_PHOSPHORYLATION+0.420
- PANCREAS_BETA_CELLS+0.400
- E2F_TARGETS+0.340
- GLYCOLYSIS+0.280
- MTORC1_SIGNALING+0.280
- HYPOXIA+0.270
- UV_RESPONSE_UP+0.260
Top 10 suppressed
- PROTEIN_SECRETION-0.480
- TGF_BETA_SIGNALING-0.460
- MITOTIC_SPINDLE-0.400
- UV_RESPONSE_DN-0.400
- HEDGEHOG_SIGNALING-0.340
- WNT_BETA_CATENIN_SIGNALING-0.340
- HEME_METABOLISM-0.300
- ANDROGEN_RESPONSE-0.190
- NOTCH_SIGNALING-0.190
- APICAL_SURFACE-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR11296848 | — | — | 0.807 |
| 2 | MNG158 | — | — | 0.806 |
| 3 | TCGA-OR-A5JE-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.784 |
| 4 | MDT-AP-2281 | Med | Medulloblastoma | 0.781 |
| 5 | TCGA-A7-A6VW-01A-21R-A33J-07 | — | E | 0.757 |
| 6 | MDT-AP-2494 | Med | Medulloblastoma | 0.751 |
| 7 | TCGA-18-3421-01A-01R-0980-07 | — | cohortSQ1 | 0.750 |
| 8 | f02aa649-f382-4f91-9a51-ce73199f8fbc | — | — | 0.750 |
| 9 | TCGA-22-4607-01A-01R-1201-07 | — | cohortSQ1 | 0.749 |
| 10 | MNG263 | — | — | 0.749 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.430 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.430 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.400 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.260 | Idelalisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.250 | Inavolisib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |